Intercept's oral drug, Ocaliva, had been approved under the accelerated approval pathway to treat patients with primary biliary cholangitis (PBC), a rare disease that causes inflammation of small bile ducts in the liver and can eventually destroy them.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/2NUDRba
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment